Albumedix

Rooted in decades of albumin science first pioneered at Delta Biotechnology and later advanced under Novozymes Biopharma, Albumedix is a Nottingham-based biotechnology company that produces recombinant human serum albumin for pharmaceutical and bioprocessing applications. The company emerged as an independent entity following Novozymes' divestment of its biopharma operations, carrying forward a well-established manufacturing and regulatory heritage.

Its flagship material, Recombumin, is expressed in Saccharomyces cerevisiae yeast and is entirely free of animal-derived and plasma-derived components. This origin gives manufacturers a consistent, traceable alternative to plasma-sourced albumin, addressing both supply-chain risk and evolving regulatory expectations around animal-free raw materials in biopharmaceutical production.

Applications Across Biologics Manufacturing

Albumin-based excipients supplied by Albumedix are used as stabilisers in vaccines, cell and gene therapy products, and protein biologics, where formulation integrity directly affects product shelf life and clinical performance. Beyond final-product formulation, Recombumin is also incorporated into cell culture media and bioprocessing workflows, supporting the growth of sensitive mammalian cell lines used in biologics development.

The company operates under pharmaceutical-grade quality systems, with its materials referenced in regulatory dossiers for licensed medicines across multiple markets. Albumedix works with global pharmaceutical manufacturers, contract development and manufacturing organisations, and advanced therapy developers seeking compliant, well-characterised albumin raw materials.

Further information is available at albumedix.com.